PL3694863T3 - Postać krystaliczna hydratu wolnej zasady lorlatynibu - Google Patents
Postać krystaliczna hydratu wolnej zasady lorlatynibuInfo
- Publication number
- PL3694863T3 PL3694863T3 PL18795807.9T PL18795807T PL3694863T3 PL 3694863 T3 PL3694863 T3 PL 3694863T3 PL 18795807 T PL18795807 T PL 18795807T PL 3694863 T3 PL3694863 T3 PL 3694863T3
- Authority
- PL
- Poland
- Prior art keywords
- free base
- crystalline form
- base hydrate
- lorlatinib free
- lorlatinib
- Prior art date
Links
- 239000012458 free base Substances 0.000 title 1
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 title 1
- 229950001290 lorlatinib Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570326P | 2017-10-10 | 2017-10-10 | |
| US201862727734P | 2018-09-06 | 2018-09-06 | |
| PCT/IB2018/057735 WO2019073347A1 (en) | 2017-10-10 | 2018-10-04 | CRYSTALLINE BASE FREE HYDRATE SHAPE OF LORLATINIB |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3694863T3 true PL3694863T3 (pl) | 2023-09-25 |
Family
ID=64049474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18795807.9T PL3694863T3 (pl) | 2017-10-10 | 2018-10-04 | Postać krystaliczna hydratu wolnej zasady lorlatynibu |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11299500B2 (pl) |
| EP (1) | EP3694863B1 (pl) |
| JP (1) | JP7153069B2 (pl) |
| KR (1) | KR102424621B1 (pl) |
| CN (1) | CN111201235B (pl) |
| AU (1) | AU2018349259B2 (pl) |
| CA (1) | CA3077508C (pl) |
| CY (1) | CY1126141T1 (pl) |
| DK (1) | DK3694863T3 (pl) |
| ES (1) | ES2952985T3 (pl) |
| FI (1) | FI3694863T3 (pl) |
| HU (1) | HUE062926T2 (pl) |
| MX (1) | MX2020003373A (pl) |
| PL (1) | PL3694863T3 (pl) |
| PT (1) | PT3694863T (pl) |
| RU (1) | RU2022109286A (pl) |
| SG (1) | SG11202002445SA (pl) |
| SI (1) | SI3694863T1 (pl) |
| TW (1) | TWI775960B (pl) |
| WO (1) | WO2019073347A1 (pl) |
| ZA (1) | ZA202001661B (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3328867T3 (da) | 2015-07-31 | 2020-11-16 | Pfizer | Krystallinsk form af fri base af lorlatinib |
| EP3770164A1 (en) | 2016-04-08 | 2021-01-27 | Pfizer Inc | Crystalline forms of lorlatinib maleate |
| WO2019209633A1 (en) * | 2018-04-23 | 2019-10-31 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| WO2021011345A1 (en) * | 2019-07-18 | 2021-01-21 | Pliva Hrvatska D.O.O | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| WO2021069571A1 (en) | 2019-10-10 | 2021-04-15 | Sandoz Ag | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
| CN111362967B (zh) * | 2020-04-28 | 2021-09-07 | 南京雷正医药科技有限公司 | 苯并氧杂二氮杂十四碳烯衍生物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| JP5808818B2 (ja) * | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| US9422226B2 (en) | 2011-06-08 | 2016-08-23 | Biogen Ma Inc. | Process for preparing high purity and crystalline dimethyl fumarate |
| GEP201606560B (en) | 2012-03-06 | 2016-10-25 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| CA2916605C (en) * | 2013-06-28 | 2018-04-24 | Pfizer Inc. | Solid forms of a macrocyclic kinase inhibitor |
| JP6609308B2 (ja) * | 2014-08-20 | 2019-11-20 | テリジーン リミテッド | キナーゼ阻害剤としての置換マクロサイクル |
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| DK3328867T3 (da) * | 2015-07-31 | 2020-11-16 | Pfizer | Krystallinsk form af fri base af lorlatinib |
| EP3770164A1 (en) | 2016-04-08 | 2021-01-27 | Pfizer Inc | Crystalline forms of lorlatinib maleate |
-
2018
- 2018-10-04 CN CN201880065709.6A patent/CN111201235B/zh active Active
- 2018-10-04 KR KR1020207010512A patent/KR102424621B1/ko active Active
- 2018-10-04 PL PL18795807.9T patent/PL3694863T3/pl unknown
- 2018-10-04 EP EP18795807.9A patent/EP3694863B1/en active Active
- 2018-10-04 JP JP2020520115A patent/JP7153069B2/ja active Active
- 2018-10-04 WO PCT/IB2018/057735 patent/WO2019073347A1/en not_active Ceased
- 2018-10-04 AU AU2018349259A patent/AU2018349259B2/en active Active
- 2018-10-04 CA CA3077508A patent/CA3077508C/en active Active
- 2018-10-04 MX MX2020003373A patent/MX2020003373A/es unknown
- 2018-10-04 FI FIEP18795807.9T patent/FI3694863T3/fi active
- 2018-10-04 HU HUE18795807A patent/HUE062926T2/hu unknown
- 2018-10-04 US US16/650,505 patent/US11299500B2/en active Active
- 2018-10-04 RU RU2022109286A patent/RU2022109286A/ru unknown
- 2018-10-04 SG SG11202002445SA patent/SG11202002445SA/en unknown
- 2018-10-04 ES ES18795807T patent/ES2952985T3/es active Active
- 2018-10-04 DK DK18795807.9T patent/DK3694863T3/da active
- 2018-10-04 PT PT187958079T patent/PT3694863T/pt unknown
- 2018-10-04 SI SI201830952T patent/SI3694863T1/sl unknown
- 2018-10-05 TW TW107135186A patent/TWI775960B/zh active
-
2020
- 2020-03-17 ZA ZA2020/01661A patent/ZA202001661B/en unknown
-
2023
- 2023-07-25 CY CY20231100357T patent/CY1126141T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI3694863T3 (fi) | 2023-08-18 |
| ES2952985T3 (es) | 2023-11-07 |
| EP3694863A1 (en) | 2020-08-19 |
| CA3077508C (en) | 2023-02-14 |
| HUE062926T2 (hu) | 2023-12-28 |
| WO2019073347A1 (en) | 2019-04-18 |
| TW201922753A (zh) | 2019-06-16 |
| CA3077508A1 (en) | 2019-04-18 |
| AU2018349259A1 (en) | 2020-04-09 |
| PT3694863T (pt) | 2023-08-23 |
| AU2018349259B2 (en) | 2021-02-18 |
| RU2020113141A3 (pl) | 2021-11-12 |
| SI3694863T1 (sl) | 2023-10-30 |
| MX2020003373A (es) | 2020-10-12 |
| EP3694863B1 (en) | 2023-06-21 |
| CY1126141T1 (el) | 2023-11-15 |
| TWI775960B (zh) | 2022-09-01 |
| DK3694863T3 (da) | 2023-07-03 |
| US20200308191A1 (en) | 2020-10-01 |
| RU2022109286A (ru) | 2022-05-06 |
| SG11202002445SA (en) | 2020-04-29 |
| JP2020536893A (ja) | 2020-12-17 |
| US11299500B2 (en) | 2022-04-12 |
| RU2020113141A (ru) | 2021-11-12 |
| JP7153069B2 (ja) | 2022-10-13 |
| CN111201235B (zh) | 2023-02-10 |
| BR112020005989A2 (pt) | 2020-09-29 |
| KR102424621B1 (ko) | 2022-07-25 |
| KR20200051781A (ko) | 2020-05-13 |
| ZA202001661B (en) | 2023-11-29 |
| CN111201235A (zh) | 2020-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288519A (en) | inhibitors of ret | |
| SG11202002445SA (en) | Crystalline form of lorlatinib free base hydrate | |
| SG10201913200XA (en) | Crystalline form of lorlatinib free base | |
| SG10202111790YA (en) | Synthesis of omecamtiv mecarbil | |
| PT3577125T (pt) | Formas cristalinas de tenofovir alafenamida | |
| IL272697A (en) | A polymorphic form of TG02 | |
| SI3380554T1 (sl) | Kristalne oblike per-kloro-gama-ciklodekstrinov | |
| GB201614939D0 (en) | Crystalline hydrate | |
| ZA201906464B (en) | Crystalline forms of (s)-afoxolaner | |
| SG10202101979TA (en) | Crystalline forms of c21h22ci2n4o2 | |
| PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
| PL3529236T4 (pl) | Krystaliczne formy erawacykliny | |
| IL269073A (en) | Crystalline forms of obeticholic acid | |
| IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
| IL253479A0 (en) | Crystalline forms of efinconazole | |
| HK40092368A (zh) | 劳拉替尼游离碱的结晶形式 | |
| HK40093795A (zh) | 劳拉替尼游离碱的结晶形式 | |
| IL270937A (en) | Crystalline forms of saltalicib |